MAPT and Alzheimer disease: Finally, integrating microbiota research with established AD biomarkers, such as amyloid-beta (Aβ) and tau, can enhance our understanding of the interactions between peripheral and central pathologies, potentially leading to more effective diagnostic and therapeutic strategies for AD.